New Haven, Conn. (PRWEB) November 22, 2013
CMDBioscience Inc., a pioneering innovator in peptide drug design and computational modeling, today announced the appointment of Tomi Sawyer, Ph.D., as the founding chair of its Scientific Advisory Board. Dr. Sawyer joins Victor Hruby, Ph.D., Bernhardt Trout, Ph.D., Benjamin Wolozin, Ph.D., and Yaoqi Zhou, Ph.D. as founding members of the Scientific Advisory Board.
Dr. Sawyer received his doctorate from the University of Arizona and is currently an adjunct professor at the University of Massachusetts (Department of Chemistry and Department of Biochemistry and Molecular Biology), the University of Massachusetts Medical School (Department of Cancer Biology), and Northeastern University (Center of Drug Discovery).
He was the founding chief scientific officer and senior vice president of drug discovery and innovative technologies at Aileron Therapeutics. Tomi has more than 30 years of pharmaceutical industry and biotech experience with multidisciplinary expertise in drug discovery and translational medicine with a focus on advancing peptides, peptidomimetics, and proteomimetics, natural products and small-molecules into the clinic. He is a former president of the American Peptide Society and founding editor-in-chief of Chemical Biology and Drug Design. Dr. Sawyer is credited with more than 320 publications and patents, and has presented nearly 200 keynote, plenary and invited lectures.
“We are delighted to have Tomi join the CMDBioscience team as the chair of our Scientific Advisory Board,” said Joseph Audie, chief executive officer of CMDBioscience. “Tomi has established a world-renowned reputation as both a scholar and leader in peptide drug discovery and brings an unrivaled wealth of expertise in peptide drug discovery and translational medicine to our Scientific Advisory Board.”
Dr. Sawyer’s responsibilities will include helping CMDBioscience to expand its cutting-edge and proprietary computational technology platform (CMDInventus) and forging strategic relationships with leading pharmaceutical and biotechnology companies.
“It’s an exciting time at CMDBioscience as we strive to be a formidable partner in peptide drug discovery,” said Dr. Audie. “The appointment of Tomi to the board further underscores our commitment to achieving the vision of transforming peptide drug discovery.”
“I’m very pleased to support the scientific and business vision of the CMDBioscience leadership team and board of directors,” said Dr. Sawyer. “The CMDBioscience drug design and computational modeling platform helps to accelerate peptide drug discovery and works with other key enabling technologies to advance future peptide therapeutics.”
CMDBioscience is a computational biotechnology company that specializes in the development and application of proprietary computational methods to enable peptide drug discovery.
CMDBioscience has developed and enjoys exclusive access to CMDInventus, our proprietary computational peptide discovery platform. Using CMDInventus, CMDBioscience can help partner organizations efficiently identify novel peptide hits, understand the structural basis of target-peptide interactions, facilitate peptide hit-to-lead optimization and help solve a myriad of other peptide discovery problems.
CMDBioscience seeks to accelerate rational peptide discovery and increase value through collaborative peptide discovery partnerships. By working with CMDBioscience, our partners will gain privileged access to CMDInventus and our expertise, ultimately producing superior peptide-based discovery outcomes and increased value.
For more information on CMDBioscience, please visit http://www.cmdbioscience.com.